‹ Back
Mazdutide
What it helps
Body fat, liver fat, blood sugar, and cholesterol and uric acid.
Sources
Read the original sources
- Mazdutide: Chinese phase 3 trial (2025 · Published abstract · checked 2026-10-08)
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. (Ji · 2022 · Abstract; full methods not assumed · checked 2026-10-13)
- Mazdutide eases fatty liver through ER stress, lipid metabolism and inflammation, Gan 2026, Pharmaceuticals (China) (Abstract · checked 2026-10-13)
- Shared mechanistic pathways of glucagon signalling in obesity and fatty liver, Neff 2025, Diabetes Obes Metab (Abstract · checked 2026-10-13)
- Type 2 diabetes and obesity: the present and future of incretin therapy, Shestakova and Bashlykova 2025, Therapeutic Archive (Russia) (Summary · checked 2026-10-13)